Amgen dans l'actualité
Développement de thérapies humaines innovantes
Tamtam a trouvé 20 articles récents sur Amgen.
- How Investors Are Reacting To Amgen (AMGN) Earnings Beat
- Amgen Inc. stock outperforms competitors on strong trading day
- Amgen announces Sjogren's trial results: Amgen stock gains 1.59 percent
- Amgen Inc Stock (AMGN) Moved Up by 3.06% on Oct 7: A Full Analysis
- Truist raises Amgen stock price target to $380 on pipeline growth
- Amgen (NASDAQ:AMGN) Stock Price Expected to Rise, Truist Financial Analyst Says
- Amgen (AMGN) Advances While Market Declines: Some Information for Investors
- Ada Visa Joins Amgen as Global Development Scientist Director
- Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
- 3,524 Amgen Inc. $AMGN Shares Sold by Colton Groome Financial Advisors LLC
- Amgen stock faces a USD 400 Cantor Fitzgerald target
- 2,546 Amgen Inc. $AMGN Shares Sold by Argent Capital Management LLC
- Why is Amgen (NASDAQ:AMGN) stock in focus as its obesity pipeline advances?
- Cantor Fitzgerald reiterates Amgen stock Neutral rating at $400 By Investing.com
- David J. Taylor Purchases Amgen and Home Depot Stocks, Sells Marathon Petroleum
- Amgen (NASDAQ:AMGN) Stock Purchase Disclosed by Rep. David Taylor
- Ohio Rep. David Taylor Bought Up to $45K Worth of Amgen Stock
- The biotech process development associate in Amgen’s grad programme
- Amgen (NASDAQ:AMGN) Scores Late-Stage Immunology Win
- More Than Skin Deep: Understanding Discoid Lupus Erythematosus
Articles collectés par Tamtam et retenus lorsqu'ils portent sur l'entreprise, des plus récents aux plus anciens. Chacun renvoie à sa source.
Vous vendez à des entreprises comme Amgen ?
Tamtam trouve les entreprises qui correspondent à votre client idéal, analyse chaque compte et vous dit qui contacter, et quand.
Trouver des entreprises similaires